Anika Therapeutics (ANIK) EBIT Margin (2010 - 2026)
Anika Therapeutics (ANIK) reported EBIT Margin of 18.53% for Q1 2026, down 216.0% year-over-year from 15.98% in Q1 2025, and down 978.31% quarter-over-quarter from 2.11% in Q4 2025.
Anika Therapeutics (ANIK) EBIT Margin (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has 17 years of EBIT Margin data on file, last reported at 18.53% in Q1 2026.
- EBIT Margin for Q1 2026 came in at 18.53%, down 216.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 10.54% (down 466.0% YoY), and the FY2025 annual result was 9.8%, down 554.0% from the prior year.
- EBIT Margin fell to 18.53% in Q1 2026 per ANIK's latest filing, from 2.11% in the prior quarter.
- Over five years, EBIT Margin peaked at 2.11% in Q4 2025 and troughed at 852.09% in Q4 2023.
- A 5-year average of 94.67% and a median of 11.62% in 2025 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2022 and 2024: EBIT Margin tumbled 56309 bps in 2022, then surged 84978 bps in 2024.
- A 5-year view of EBIT Margin shows it stood at 588.55% in 2022, then sank by 45 bps to 852.09% in 2023, then soared by 100 bps to 2.3% in 2024, then surged by 192 bps to 2.11% in 2025, then sank by 978 bps to 18.53% in 2026.
- Business Quant data shows ANIK's EBIT Margin at 18.53% in Q1 2026, 2.11% in Q4 2025, and 11.62% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 20.77% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 23.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -122.23% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -12.88% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | Anika Therapeutics | 197.89 Mn | 131.10 Mn | 19.00 Mn | -18.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.53% |
| Dec 31, 2025 | 2.11% |
| Sep 30, 2025 | -11.62% |
| Jun 30, 2025 | -14.81% |
| Mar 31, 2025 | -16.37% |
| Dec 31, 2024 | -2.30% |
| Sep 30, 2024 | -0.27% |
| Jun 30, 2024 | -5.89% |
| Mar 31, 2024 | -8.63% |
| Dec 31, 2023 | -852.09% |
| Sep 30, 2023 | -18.51% |
| Jun 30, 2023 | -8.20% |
| Mar 31, 2023 | -33.10% |
| Dec 31, 2022 | -588.55% |
| Sep 30, 2022 | -14.40% |
| Jun 30, 2022 | -8.53% |
| Mar 31, 2022 | -9.69% |
| Dec 31, 2021 | -25.47% |
| Sep 30, 2021 | 3.29% |
| Jun 30, 2021 | 24.07% |